Glenmark Pharmaceuticals Ltd Q3 FY2024 Concall Summary

Key Takeaways

• A one-time India reset masks underlying strength: Reported India sales collapsed to ₹262 cr from ₹1,075 cr as the company deliberately starved the channel to fix years-old distribution inefficiencies. Secondary sales grew 12%, and the ₹1,000 cr quarterly run rate resumes in Q4.
• FY25 EBITDA is set to jump, but management won't size it yet: A ~$30-35 mn R&D cost drop from the IGI restructuring, Ryaltris scale-up, and operating leverage across Europe and LatAm converge next year. Management calls it a "significant step up" but defers a specific number to the Q4 call.
• The balance sheet flips to net cash by March: The ~₹5,000 cr GLS divestment will repay nearly all of the ~₹4,900 cr debt, making Glenmark net cash positive by end of FY24. The U.S. liability is also nearly extinguished, with only ₹3 cr remaining.
• Ryaltris is the near-term margin engine, Envafolimab the sequel: Ryaltris carries "huge" margins on a profit-share structure and is targeting ~$80 mn in booked sales for FY25. Envafolimab, a licensed PD-L1, is positioned as the next Ryaltris for the 3-4 years after.
• What to watch next quarter: The specific EBITDA number management commits to for FY25, the FDA's response to the Monroe meeting request, and whether the India reported sales snap back to the promised ~₹1,000 cr.

The India Distribution Reset

• A deliberate, one-time inventory correction: Glenmark consolidated multiple stock points and reduced channel inventory to industry norms by not supplying the channel in Q3. This caused reported sales to print at ~₹850-870 cr instead of the normalized ~₹1,100 cr, a gap filled entirely by existing channel stock. No write-off occurred.
• Secondary sales tell the real story: IQVIA secondary sales grew 11.9% in Q3 and 11.5% MAT, outpacing the market's 8% and 9.5%. Cardiac, dermatology and respiratory drove the outperformance. Post-correction, reported and secondary sales will align.
• Working capital got a structural lift: The consolidation of stock points directly improved working capital, with debt already declining. The company targets ~100 days of working capital for FY25.
• Q4 snaps back: Management expects India sales to return to the normal ~₹1,000 cr quarterly trend in Q4, with sustained ~10-12% growth going forward.

Glenn Saldanha: "So I think the primary reason we did the one-time restructuring was because we had certain inefficiencies in the distribution channel, which we wanted to correct, right? And what we did is by consolidating all the stock points, right, we are -- we're reducing the inventory substantially in the channel."

The FY25 EBITDA Inflection

• Three drivers converge next year: The IGI alliance restructuring drops R&D spend from ~$75-80 mn to ~$45-50 mn, with ~$30-35 mn flowing straight to EBITDA. Ryaltris scales up with very high margins on its profit-share structure. Europe and Latin America deliver operating leverage as their branded and generic businesses grow.
• Management promises consistency thereafter: Beyond the FY25 step-up, the commitment is that EBITDA margins will improve every year on a consistent basis, driven by operating leverage, branded product launches, and Ryaltris scale. No specific trajectory or terminal margin was given.
• Guidance is a Q4 event: Management declined to put a number on the FY25 EBITDA bump, stating it typically guides at the end of Q4. An analyst's request for a two-year EBITDA view was explicitly deflected.

Glenn Saldanha: "But if you take the R&D flow-through that we just discussed and you assume Ryaltris improvement, all the synergies that we are seeing in the operating leverage, that you'll see in various geographies, right, it will be a significant step up in terms of overall EBITDA."

Ryaltris and the Specialty Pipeline

• Ryaltris is scaling globally: Already the leading nasal spray for allergic rhinitis in South Africa 18 months post-launch, it launched in 4 additional Middle Eastern markets in Q3 and continues gaining share in Russia. Approved in 18 more markets for launch over the next 3-6 months, with a partner in Mainland China targeting a mid-2025 launch.
• The margin profile is exceptional: Ryaltris operates on a profit-share structure that carries "huge" margins, making its scale-up the primary driver of the promised EBITDA improvement next year. Management targets ~$80 mn in booked sales for FY25, with peak sales described as "substantial" over the next 5 years and an aspirational 15-20% overall market share.
• Envafolimab is the next act: The licensed PD-L1 targets emerging markets where KEYTRUDA alone has ~$3-4 bn in sales. Management sees it as "the next Ryaltris," with Ryaltris dominating the next 3-4 years and Envafolimab thereafter. No specific timeline or sales target was provided.
• IGI pipeline reads out in FY25: Three oncology assets (2001, 1442, 54276/HPK1) are expected to read out in FY25. All have blockbuster potential, and management acknowledges not all three will move forward, but even one or two progressing provides meaningful pipeline runway. All will be partnered at some stage.

Glenn Saldanha: "Yes, Nitin. The margins will be huge. And that is exactly why we are talking about EBITDA for next year going up significantly, right?"

U.S. Business: Rebuilding Through Injectables and Respiratory

• The Monroe plant is ready for FDA re-engagement: All remediation work is complete, process validation batches have started, and a meeting request has been submitted to the FDA. Management hopes to restart commercial production post-inspection, with ~2 products commercialized in FY25 and a ramp-up thereafter. The facility currently carries significant operating costs with no revenue, so commercialization will provide operating leverage.
• Three platforms underpin the U.S. strategy: An injectable portfolio built on Monroe plus exclusive partnerships for 4-5 marketed injectables, a respiratory portfolio with 2 nasal sprays expected in FY25 and a generic Flovent pMDI in FY26, and drug-device products. The legacy dermatology and oral contraceptive platforms remain.
• Near-term launches are already flowing: Seven products launched in Q3, including four injectables (Fosphenytoin, Octreotide, Posaconazole, Ketorolac). These launches are likely to positively impact the U.S. business from Q4 FY24 onwards, after a ~9% YoY decline this quarter due to a lack of significant new launches in preceding quarters.
• Partnership details remain undisclosed: Management declined to share the commercial structure of its injectable partnerships or the specific market values of FY25/FY26 U.S. launches, stating it had given "enough of thoughts."

Balance Sheet Transformation

• GLS divestment makes Glenmark net cash positive: The ~₹5,000 cr in net proceeds will repay nearly all of the ~₹4,900 cr debt, with the transaction expected to culminate in early March 2024. The company will be net cash positive by end of FY24.
• U.S. liability nearly gone: Almost all of the U.S. liability has been paid off, with only ₹3 cr remaining.
• Dividend policy remains undefined: When asked about dividends post the GLS windfall, management only said it would be discussed at the year-end Board meeting and noted the company has been frugal historically. No commitment was made. The GLS proceeds are treated as a long-term capital gain, not a dividend from a subsidiary.

V. S. Mani: "That money will go purely to pay off the debt which we have in our books, which is close to what about INR4,900 crores, So that's why we're guiding that we'll be net cash positive at the end of the year."

Regional Performance Snapshot

Guidance & Commitments

Key Metrics